Kronos Bio, Inc. Common Stock
KRON
KRON: Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
moreShow KRON Financials
Recent trades of KRON by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by KRON's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine Dec. 06, 2022
-
Patent Title: Hydrates of polymorphs of 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-a]pyrazin-8-amine bisemsylate as syk inhibitors Jul. 12, 2022
-
Patent Title: Crystalline forms of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as syk inhibitors May. 24, 2022
-
Patent Title: Substituted pyrazolo[1,5-a]pyrimidines for modulating cdk9 activity Oct. 26, 2021
-
Patent Title: Imidazopyridines syk inhibitors Nov. 24, 2020
-
Patent Title: Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine Nov. 10, 2020
Federal grants, loans, and purchases
Followers on KRON's company Twitter account
Number of mentions of KRON in WallStreetBets Daily Discussion
Recent insights relating to KRON
Recent picks made for KRON stock on CNBC
ETFs with the largest estimated holdings in KRON
Flights by private jets registered to KRON